阿奇霉素治疗23SrRNA的A2063G基因位点突变肺炎支原体肺炎患儿的临床观察

打开文本图片集

【中图分类号】R725.6 【文献标志码】A

Clinical efficacy of azithromycin for treatment of Mycoplasma pneumoniae pneumonia with gene mutations at site A2063G of 23S rRNA in children

LiWen'，Luo Tongyong'，Wang Fei'，Zhang Bo2 ，Jiang Yongxian'，Hu Siqi' （1.DepartmentofClinical Pharmacy，SichuanProvincial Maternityand Child Health Care Hospital/Sichuan Provincial Hospital for Womenand Children/Womenand Children'sHospitalAfliatedto Chengdu Medical Collge; 2.Department of Pharmacy，Yibin Second Hospital of Traditional Chinese Medicine） 【AbstractlObjective：ToobservetheclincaleficacyofazithromyciforthetreatmentofMycoplasmapneumoniaepneumonia（MPP） withgene mutationsatsiteA2063Gof23SrRNAinchildren.Methods：Data wereretrospectivelycollctedfor242childrendiagnosed with MPPatSichuanProvincial MaterityandChildHealthCareHospitalfromJanuarytoDecember2023，inwhomMPPwasdetected usingtargetednextgeeratiosequencing（tNGS）.Acodingtotepresenceobsenceofutations，techldrenwereclasifedinto mutation group（88cases）andnon-mutationgroup（154cases）.Results：Gene mutationsatsiteA2063Gof23SrRNA weredetected in 88patients.ThechestX-raysofbothgroupsshowedmorelesionsintherightlung thanintheleftlung.Bothgroupsweretreatedwith azithromycindompardfordifrecsiages，uratofve，Cactiveproteivel，tomprovemetofca， days of medication，and response rate，with no significant diferences found in the above indicators（ P >0.05）.However，the duration of respiratory symptoms was significantly longer in the mutation group than in the non-mutation group ⌊（ 11.51±3.31 ） d vs. （ 10.06± （20 3.63） d，P<0.05] .Conclusion：Azithromycin is effective in treating MPP with gene mutations at site A2O63G of 23S rRNA. [Kev wordslazithromvein ： macrolide resistance：mvconlasma nneumonia：23S rRNA resistane gene

肺炎支原体（mycoplasma pneumoniae，MP）是儿童呼吸道感染最常见的病原体之一，MP肺炎占住院儿童社区获得性肺炎的 10%～40% ，每3～7年出现周期性暴发现象，且流行期间支原体载量大，感染较为严重[1-3]。（剩余8378字）